secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-01-12T23:59:59+00:00
Accession:  0001564590-22-001074
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Pharma receives $15M milestone from Neurocrine after FDA accepts pediatric epilepsy study expansion
--------------------------------------------------------------------------------

- FDA accepted protocol amendment to expand Phase 2 study of NBI-921352 to children aged 2–11 with SCN8A-DEE.
- Xenon receives aggregate $15M: $6.75M cash plus $8.25M equity (258,986 shares at $31.855, a 15% premium to 30-day VWAP).
- Full IND acceptance triggered per amendment to 2019 Collaboration Agreement with Neurocrine Biosciences.
- Neurocrine's NBI-921352 is a selective Nav1.6 sodium channel inhibitor; two ongoing Phase 2 trials in epilepsy.
- Xenon potential for future clinical, regulatory, and commercial milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022001074/0001564590-22-001074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022001074/xene-8k_20220111.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-001074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer